SERPINE1 and non-small cell lung carcinoma: These observations, together with the results presented here, strongly suggest that stromal and, more precisely, senescent TA-MSCs derived SERPINE1/PAI1 contributes to the progression and resistance of NSCLC, making it a potential target for lung cancer therapy.